Pharmacological suicide prevention under special consideration of lithium salts;Möglichkeiten medikamentöser suizidprävention unter besonderer berücksichtigung der lithiumsalze

Psychiatrische Praxis, Supplement

Volumn 34, Issue 3, 2007, Pages

  Müller Oerlinghausen, Bruno ^a,b  

^a Laboratory Center Berlin   (Germany)

^b International Group for the Study of Lithium Treated Patients (IGSLI)   (Germany)

Author keywords

Antidepressant; Lithium; Mood stabilizer; Prevention; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; LITHIUM SALT; MOOD STABILIZER; VALPROIC ACID;

BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MORTALITY; PATIENT COMPLIANCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SHORT SURVEY; SUICIDE; SYSTEMATIC REVIEW;

EID: 34648816547     PISSN: 16118332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (36)

1. Oquendo MA, Chandbury SR, Manu JJ. Pharmacotherapy of suicidal behaviour in bipolar disorder. Arch Suicide Res 2005; 9: 237-250
2. Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants - a key issue in the prevention of suicide. An analysis of 5281 suicides in Sweden 1992-1994. Acta Psychiatr Scand 1997; 96: 94-100
3. Isacsson G. Frequency of suicides reduced with 25 percent: Probably by the increased use of antidepressive agents. Lakartidningen 2000; 97: 1644-1650
4. Wolfersdorf M, Mauerer C, Franke C. Suizidalität und Antriebssteigerung: Provokation und/oder Prävention von Suizidgefahr durch Psychopharmaka. In: Bronisch T, Felber W, Wolfersdorf M (Hrsg): Neurobiologie suizidalen Verhaltens. Regensburg: Roderer Verlag, 2001: 303-323
5. van Praag MH. A Stubborn Behaviour: the failure of antidepressants to reduce suicide rates. Worl J Biol Psychiatry 2003; 4: 184-191
6. Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs. untreated bipolar and depressed patients: a preliminary report. Int J Psychiatry Clin Pract 1998; 2: 115-119
7. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in mood-disorder patients with and without longterm medication: a 40 to 44 years follow-up. Arch Suicide Res 2005; 9: 279-300
8. Bauer M, Whybrow PC, Angst J et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part I: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43
9. Bauer M, Whybrow PC, Angst A et al. WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subtreshold depressions. World J Biol Psychiatry 2002; 3: 67-84
10. Arzneimittelkommission der deutschen Ärzteschaft. Empfehlungen zur Therapie der Depression. 2. Auflage. Arzneiverordnung in der Praxis; Bd. 33 (Sonderheft 1) 2006
11. Harris EC, Banaclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53
12. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132-136
13. Müller-Oerlinghausen B, Ahrens B, Felber W. The suicide-preventive and mortality-reducing effect of lithium. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds): Lithium in Neuropsychiatry. Abingdon, Oxon UK: Informa, 2006: 179-192
14. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473
15. Machritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3): CD003196
16. Müller-Oerlinghausen B, Felber W, Berghöfer A, Lauterbach E, Ahrens B. The Impact of lithium-long-term medication on suicidal behaviour and mortality of bipolar patients. Archives Suic Res 2005; 9: 307-319
17. Guzzetta F, Tondo L, Centurrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383
18. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
19. Barraclough B. Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry 1972; 121: 391-392
20. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992; 25: 261-270
21. Felber W, Kyber A. Suizide und Parasuizide während und außerhalb einer Lithiumprophylaxe. In: Müller-Oerlinghausen B, Berghöfer A (Hrsg): Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart: Georg Thieme Verlag, 1994: 53-59
22. Ahrens B, Müller-Oerlinghausen B. Lithiumprophylaxe und Mortalität bei Langzeitbehandlung: Die Mortalität normalisiert sich bei Langzeitbehandlung. Psycho 1990; 16: 489-495
23. Coppen A, Standish-Barry H, Bailey J et al. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7
24. Müller-Oerlinghausen B, Ahrens B, Grof F et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizo-affective illness. Acta Psychiatr Scand 1992; 86: 218-222
25. Wolf T, Müller-Oerlinghausen B, Ahrens B et al. How to interpret findings on mortality of long-term lithium treated manic-depressive patients? Critique of different methodological approaches. J Affect Disord 1996; 39: 127-132
26. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103-107
27. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161
28. Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium. A complete population study in 362 patients. Pharmacopsychiatry 1995; 28: 8-13
29. Kallner G, Lindelius R, Petterson U et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000; 33: 8-13
30. Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behaviour in major mood disorders. In: Stoff DM, Mann JJ (eds): The Neurobiology of Suicide: From the Bench to the Clinic. Ann NY Acad Sci 1997; 836: 339-351
31. Berghöfer A, Bauer M, Müller-Oerlinghausen B. Antisuicidal effect of lithium as a criterion for the selection of appropriate long-term medication in bipolar patients. In: Kaschka WP (eds): Perspectives in Affective Disorders. Advanced Biological Psychiatry. Basel: Karger, 2002; 21: 1-9
32. Goldacre M, Seagroatt V, Hawton K. Suicide after discharge from psychiatric inpatient care. Lancet 1993; 342: 283-286
33. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1988; 153: 741-751
34. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988; 153: 752-757
35. Lehmann HE, Fenton FR, Deutsch M et al. An 11-year follow-up study of 110 depressed patients. Acta Psychiatr Scand 1988; 78: 57-65
36. Berghöfer A. Economics of lithium prophylaxis in bipolar patients. In: Bauer M, Graf P, Müller-Oerlinghausen B (eds): Lithium in Neuropsychiatry. Abingdon, Oxon UK: Informa, 2006: 505-511